Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.67 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.62 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.62 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.62 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.48 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 18/20 | 0.67 |
| ▸ | KDM1B | Q8NB78 | 4/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15285969 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL29786384 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15282062 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL30639424 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL31329562 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL16116285 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL15282133 | 1.00 | KDM1A (0.67) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15011508 | 0.98 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL15011361 | 0.98 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C | |
| SCHEMBL247873 | 0.98 | KDM1A (0.69) | KDM1AKDM1BKCNH2HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114062567-B | Separation and detection method of (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | 江苏威凯尔医药科技有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-110412188-B | Method for separating and determining isomer impurities of ticagrelor intermediate | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | claimed |
| CN-114062567-A | Separation and detection method of (1R,2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | 江苏威凯尔医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-119798263-A | Ticagrelor acetyl derivative and preparation method thereof | 南通常佑药业科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| CN-114062567-B | Separation and detection method of (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | 江苏威凯尔医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114062567-B | Separation and detection method of (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | 江苏威凯尔医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114062567-B | Separation and detection method of (1R, 2S) -2- (3, 4-difluorophenyl) cyclopropylamine hydrochloride and related substances thereof | 江苏威凯尔医药科技有限公司 | 2023-04-07 | — | — | CN | disclosed |
| WO-2022195522-A1 | INHIBITORS OF ANO6 AND THEIR USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-09-22 | — | — | WO | disclosed |
| CN-111233673-B | Preparation method of chiral aromatic cyclopropylamine and salt thereof and intermediate used in preparation method | 苏州元兴生物医药有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2022157686-A1 | INHIBITORS OF ANOCTAMIN 6 PROTEIN AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-07-28 | — | — | WO | disclosed |
| CN-110412188-B | Method for separating and determining isomer impurities of ticagrelor intermediate | 广东东阳光药业有限公司 | 2022-07-26 | — | — | CN | disclosed |
| US-9670210-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| US-9278972-B2 | Synthesis of triazolopyrimidine compounds | LEK PHARMACEUTICALS D.D. (SI) | 2016-03-08 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| CN-104603098-A | Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts | SANDOZ AG | 2015-05-06 | — | — | CN | disclosed |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | LEK PHARMACEUTICALS D.D. (SI) | 2014-12-18 | — | — | US | disclosed |
| EP-2794575-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK Pharmaceuticals d.d. (SI) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013144295-A1 | SYNTHESIS OF 2-(3,4-DIFLUOROPHENYL)CYCLOPROPANAMINE DERIVATIVES AND SALTS | SANDOZ AG (CH) | 2013-10-03 | — | — | WO | disclosed |
| EP-2644590-A1 | Synthesis of 2-(3,4-difluorophenyl)cyclopropanamine derivatives and salts | LEK Pharmaceuticals d.d. (SI) | 2013-10-02 | — | — | EP | disclosed |
| WO-2013092900-A1 | SYNTHESIS OF TRIAZOLOPYRIMIDINE COMPOUNDS | LEK PHARMACEUTICALS D.D. (SI) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | KCNH2 2919/4885HTR2A 1035/4885HTR2C 1508/4885 |
| US-20140371449-A1 | Synthesis of Triazolopyrimidine Compounds | TBXAS1, TYMS, FDPS | KCNH2 2775/4885HTR2A 388/4885HTR2C 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.